Biochemical characterization of plasma-derived tissue factor pathway inhibitor: Post-translational modification of free, full-length form with particular reference to the sugar chain

Journal of Thrombosis and Haemostasis

Volumn 7, Issue 1, 2009, Pages 111-120

  Mori, Y ^a   Hamuro, Tsutomu ^a   Nakashima, T ^a   Hamamoto, T ^a   Natsuka, S ^b   Hase, S ^b   Iwanaga, S ^a  

^a Chemo Sero Therapeutic Research Institute   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

Free form; Plasma derived; Post translational modification; Sugar chain; Tissue factor pathway inhibitor

Indexed keywords

ACETYLCYSTEINE DERIVATIVE; ASPARAGINE; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 8; GLYCOPROTEIN; GLYCOSIDASE; HEPARIN; SERINE; SIALIDASE; SIALOPROTEIN; SUGAR; THREONINE; TISSUE FACTOR PATHWAY INHIBITOR;

ANION EXCHANGE; ANTIBODY AFFINITY; ARTICLE; BINDING AFFINITY; BIOCHEMISTRY; BLOOD ANALYSIS; CHO CELL; ENZYME ACTIVITY; ENZYME DEGRADATION; HUMAN; HUMAN CELL; NONHUMAN; PEPTIDE MAPPING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN PURIFICATION; PROTEIN STRUCTURE; REVERSED PHASE LIQUID CHROMATOGRAPHY; STRUCTURE ANALYSIS; SULFATION;

CARBOHYDRATES; CHROMATOGRAPHY; GLYCOPROTEINS; HUMANS; LIPOPROTEINS; PHOSPHORYLATION; PROTEASE INHIBITORS; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 57749179741     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2008.03222.x     Document Type: Article

References (36)

1. Wun TC, Kretzmer KK, Girard TJ, Miletich JP, Broze GJ Jr. Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains. J Biol Chem 1988; 263: 6001-4.
2. Wesselschmidt R, Likert K, Girard T, Wun TC, Broze GJ Jr. Tissue factor pathway inhibitor: The COOH-terminus is required for optimal inhibition of factor Xa. Blood 1992; 79: 2004-10.
3. Piro O, Broze GJ Jr. Role for the Kunitz-3 domain of tissue factor pathway inhibitor-α in cell surface binding. Circulation 2004; 110: 3567-72.
4. Bajaj MS, Kuppuswamy MN, Saito H, Spitzer SG, Bajaj SP. Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: Evidence that endothelium is the principal site of its synthesis. Proc Natl Acad Sci U S A 1990; 87: 8869-73.
5. Novotny WF, Brown SG, Miletich JP, Rader DJ, Broze GJ Jr. Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. Blood 1991; 78: 387-93.
6. Barrowcliffe TW, Eggleton CA, Stocks J. Studies of anti-Xa activity in human plasma II: The role of lipoproteins. Thromb Res 1982; 27: 185-95.
7. Broze GJ Jr, Lange GW, Duffin KL, MacPhail M. Heterogeneity of plasma tissue factor pathway inhibitor. Blood Coagul Fibrinolysis 1994; 5: 551-9.
8. Sandset PM, Abildgaard U, Larsen ML. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 1988; 50: 803-13.
9. Novotny WF, Palmier M, Wun TC, Broze GJ Jr, Miletich JP. Purification and properties of heparin-releasable lipoprotein-associated coagulation inhibitor. Blood 1991; 78: 394-400.
10. Lupu C, Goodwin CA, Westmuckett AD, Emeis JJ, Scully MF, Kakkar VV, Lupu F. Tissue factor pathway inhibitor in endothelial cells colocalizes with glycolipid microdomains/caveolae - regulatory mechanism(s) of the anticoagulant properties of the endothelium. Arterioscler Thromb Vasc Biol 1997; 17: 2964-74.
11. Zhang J, Piro O, Lu L, Broze GJ Jr. Glycosyl phosphatidylinositol anchorage of tissue factor pathway inhibitor. Circulation 2003; 108: 623-7.
12. Novotny WF, Girard TJ, Miletich JP, Broze GJ Jr. Platelets secrete a coagulation inhibitor functionally and antigenically similar to the lipoprotein associated coagulation inhibitor. Blood 1988; 72: 2020-5.
13. Kamikura Y, Wada H, Yamada A, Shimura M, Hiyoyama K, Shiku H, Tanigawa M, Nishikawa H, Yamada N, Isaka N, Nakano T, Kumeda K, Kato H. Increased tissue factor pathway inhibitor in patients with acute myocardial infarction. Am J Hematol 1997; 55: 183-7.
14. Novotny WF, Girard TJ, Miletich JP, Broze GJ Jr. Purification and characterization of the lipoprotein-associated coagulation inhibitor from human plasma. J Biol Chem 1989; 264: 18832-7.
15. Hansen JB, Huseby KR, Huseby NE, Ezban M, Nordoy A. Tissue factor pathway inhibitor in complex with low density lipoprotein isolated from human plasma does not possess anticoagulant function in tissue factor-induced coagulation in vitro. Thromb Res 1997; 85: 413-25.
16. Dahm AEA, Andersen TO, Rosendaal F, Sandset PM. A novel anticoagulant activity assay of tissue factor pathway inhibitor I (TFPI). J Thromb Haemost 2005; 3: 651-8.
17. Wun TC, Huang MD, Kretzmer KK, Palmier MO, Day KC, Bulock JW, Fok KF, Broze GJ Jr. Immunoaffinity purification and characterization of lipoprotein-associated coagulation inhibitors from Hep G2 hepatoma, Chang liver, and SK hepatoma cells -a comparative study. J Biol Chem 1990; 265: 16096-101.
18. Pedersen AH, Nordfang O, Norris F, Wiberg FC, Christensen PM, Moeller KB, Meidahl-Pedersen J, Beck TC, Norris K, Hedner U. Recombinant human extrinsic pathway inhibitor - production, isolation, and characterization of its inhibitory activity on tissue factor-initiated coagulation reactions. J Biol Chem 1990; 265: 16786-93.
19. Day KC, Hoffman LC, Palmier MO, Kretzmer KK, Huang MD, Pyla EY, Spokas E, Broze GJ Jr, Warren TG, Wun TC. Recombinant lipoprotein-associated coagulation inhibitor inhibits tissue thromboplastin-induced intravascular coagulation in the rabbit. Blood 1990; 76: 1538-45.
20. Wun TC, Kretzmer KK, Palmier MO, Day KC, Huang MD, Welsch DJ, Lewis C, Wolfe RA, Zobel JF, Lange GW, Frazier RB, Bild GS, Peel MA, Shell RE, Horn NA, Junger KD, Foy BA, Gustafson ME, Leimgruber RM, Novotny WF. Comparison of recombinant tissue factor pathway inhibitors expressed in human SK hepatoma, mouse C127, baby hamster kidney, and Chinese hamster ovary cells. Thromb Haemost 1992; 68: 54-9.
21. Diaz-Collier JA, Palmier MO, Kretzmer KK, Bishop BF, Combs RG, Obukowicz MG, Frazier RB, Bild GS, Joy WD, Hill SR, Duffin KL, Gustafson ME, Junger KD, Grabner RW, Galluppi GR, Wun TC. Refold and characterization of recombinant tissue factor pathway inhibitor expressed in Escherichia coli. Thromb Haemost 1994; 71: 339-46.
22. Girard TJ, McCourt D, Novotny WF, MacPhail LA, Likert KM, Broze GJ Jr. Endogenous phosphorylation of the lipoprotein-associated coagulation inhibitor at serine-2. Biochem J 1990; 270: 621-5.
23. 4 -4GalNAcβ1,4GlcNAcβ1,2Manα. J Biol Chem 1992; 267: 19140-6.
24. Nakahara Y, Miyata T, Hamuro T, Funatsu A, Miyagi M, Tsunasawa S, Kato H. Amino acid sequence and carbohydrate structure of a recombinant human tissue factor pathway inhibitor expressed in Chinese hamster ovary cells: One N- and two O-linked carbohydrate chains are located between Kunitz domains 2 and 3 and one N-linked carbohydrate chain is in Kunitz domain 2. Biochemistry 1996; 35: 6450-9.
25. Broze GJ Jr, Girard TJ, Novotny WF. Regulation of coagulation by a multivalent Kunitz-type inhibitor. Biochemistry 1990; 29: 7539-46.
26. Abumiya T, Enjyoji K, Kokawa T, Kamikubo Y, Kato H. An anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody recognized the third Kunitz domain (K3) of free-form TFPI but not lipoprotein-associated forms in plasma. J Biochem (Tokyo) 1995; 118: 178-82.
27. Kuraya N, Hase S. Release of O-linked sugar chains from glycoproteins with anhydrous hydrazine and pyridylamination of the sugar chains with improved reaction conditions. J Biochem (Tokyo) 1992; 112: 122-6.
28. Hase S, Ibuki T, Ikenaka T. Reexamination of the pyridylamination used for fluorescence labeling of oligosaccharides and its application to glycoproteins. J Biochem (Tokyo) 1984; 95: 197-203.
29. Kuraya N, Hase S. Analysis of pyridylaminated O-linked sugar chains by two-dimensional sugar mapping. Anal Biochem 1996; 233: 205-11.
30. Hase S. High-performance liquid chromatography of pyridylaminated saccharides. In: Ginsburg V, ed. Methods in Enzymology vol. 230. New York: Academic Press Inc., 1994: 225-37.
31. Sprecher CA, Kisiel W, Mathewes S, Foster DC. Molecular cloning, expression, and partial characterization of a second human tissue-factor-pathway inhibitor. Proc Natl Acad Sci U S A 1994; 91: 3353-7.
32. Kaumeyer JF, Polazzi JO, Kotick MP. The mRNA for a proteinase inhibitor related to the HI-30 domain of inter-alpha-trypsin inhibitor also encodes alpha-1-microglobulin (protein HC). Nucleic Acids Res 1986; 14: 7839-50.
33. Hochstrasser K, Schonberger OL, Rossmanith I, Wachter E. Kunitz-type proteinase inhibitors derived by limited proteolysis of the inter-α-trypsin inhibitor, V. Hoppe Seylers Z Physiol Chem 1981; 362: 1357-62.
34. Toyoda H, Ikei T, Demachi Y, Toida T, Imanari T. Structural analysis of the N-linked oligosaccharides from human urinary trypsin inhibitor. Chem Pharm Bull 1992; 40: 2882-4.
35. Ikeo K, Takahashi K, Gojobori T. Evolutionary origin of a Kunitz-type trypsin inhibitor domain inserted in the amyloid β precursor protein of Alzheimer's disease. J Mol Evol 1992; 34: 536-43.
36. Belaaouaj AA, Li A, Wun TC, Welgus HG, Shapiro SD. Matrix metalloproteinases cleave tissue factor pathway inhibitor - Effects on coagulation. J Biol Chem 2000; 275: 27123-8.